Executive Summary
CMS's proposed 2026 TAVR National Coverage Determination and the STS TVT Registry's future sit at the center of today's file. Bowdish warns in Annals of Thoracic Surgery that dismantling registry infrastructure would leave the field navigating expanded low-risk TAVR without the map. The STS risk model for SAVR-after-TAVR lands as the first validated tool quantifying the excess surgical hazard when TAVR is placed first — an explicit rejoinder to lifetime-management assumptions. TRISCEND II 1-year echo data show 95.3% of TTVR patients achieved mild TR with measurable RV reverse remodeling, hardening the ESC 2025 Class IIa case for transcatheter tricuspid therapy while ACC/AHA 2020 still makes no recommendation in this space. The transcatheter field is being asked to prove its long-tail assumptions the same week regulators consider expanding its footprint.
- STS-PROM ≥5.75 predicted post-TAVI AKI with 72% sensitivity, 80% specificity in an 82-patient single-center cohort (AUC 0.732) (Curr Probl Cardiol).
- TTVR drove significant increases in RV stroke volume and cardiac output at 1 year with concurrent drops in RV systolic function metrics, reflecting preload unloading rather than deterioration (JACC Imaging).
- COMPARE-TAVI 1 substudy documents indexed stroke volume recovery in low-flow AS after TAVI, sharpening patient selection in the LFLG phenotype (JACC Imaging).
- Edwards trades flat at $85.73 with margins holding, but reports of an FTC penalty muddy the pre-earnings setup.
What to watch: Edwards Q2 earnings drop July 23 — first read on TAVR volumes into the CMS coverage revision window.
Aortic Valve (TAVR/TAVI)
[NOTABLE] Michael Bowdish's Annals editorial on the 2026 CMS TAVR NCD makes an uncomfortable point: as coverage broadens toward younger, lower-risk anatomies, the STS/ACC TVT Registry — the mechanism tracking signals like PPM rates, PVL, and stroke — is the only real-time surveillance we have. Losing or defanging it while indications expand is bad epistemics. ESC 2025 and ACC/AHA 2020 lifetime-management frameworks both rest on assumptions about durability, valve-in-valve feasibility, and reintervention risk that only registries at scale can validate. Without that infrastructure, the field is pricing in assumptions it cannot audit.
Two mechanistic contributions arrive alongside. The STS-PROM AKI substudy (single-center, N=82, retrospective) identifies a threshold of ≥5.75 for predicting post-TAVI AKI — hypothesis-generating at this sample size, not practice-changing. More clinically actionable is the COMPARE-TAVI 1 substudy showing indexed stroke volume improvement in low-flow AS post-TAVI, reinforcing that LFLG patients — a group both ACC/AHA 2020 and ESC 2025 rate Class I for intervention when LVEF is reduced — recover hemodynamically. ACC/AHA 2020 and ESC 2025 align that CT calcium scoring (≥2000 AU men, ≥1200 AU women) should confirm true severe AS before intervention in this phenotype; the COMPARE-TAVI data support that appropriately selected LFLG patients benefit. A separate HeartRhythm case report describes delayed bradycardia-dependent LBBB post-TAVI as a potential pacing indication — a reminder that conduction sequelae remain incompletely mapped a decade into widespread use.
Tricuspid Valve (TriClip, TTVR)
[NOTABLE] The TRISCEND II echo substudy in JACC Imaging (400 patients randomized 2:1 to EVOQUE TTVR vs. medical therapy) reports 95.3% mild-or-less TR at 1 year in the TTVR arm versus 2.3% in controls, with significant IVC diameter reduction, RV diastolic reverse remodeling, and increases in RV stroke volume and cardiac output. The concurrent drop in RV systolic function metrics is preload-mediated, not a deterioration signal, and reads consistent with the physiology of acute TR elimination. ESC 2025 cites TRISCEND II as foundational to its Class IIa (LOE A) recommendation for transcatheter tricuspid therapy in high-risk symptomatic severe TR without severe RV dysfunction or pre-capillary pulmonary hypertension. ACC/AHA 2020 makes no recommendation on transcatheter tricuspid therapy — the trials had not read out at the time of publication.
The surgical counterpoint is material. Isolated TV surgery mortality historically ran 8–20% driven by late referral; contemporary cohorts with earlier referral have improved, and ESC 2025 upgraded symptomatic severe primary TR surgery to Class I — a stronger surgical recommendation than existed in any prior guideline. TRISCEND II does not resolve the surgery-versus-transcatheter question for operable patients; it was not designed to. It establishes that TTVR achieves durable TR elimination with RV reverse remodeling in patients who would not be offered surgery.
Mitral Valve (MitraClip, PASCAL, TMVR)
A pointed EHJ letter flags potential exacerbation of systolic anterior motion during transcatheter mitral edge-to-edge repair — a mechanism worth internalizing given ESC 2025's Class I upgrade of TEER for ventricular secondary MR. SAM is a well-characterized surgical repair complication governed by posterior leaflet height, aorto-mitral angle, and septal thickness; it has been under-discussed as a TEER hazard. COAPT-derived selection criteria (LVEF 20–50%, LVESD ≤70mm, SPAP ≤70mmHg) do not screen for SAM substrate. Operators expanding TEER volumes on the strength of RESHAPE-HF2 and 5-year COAPT data need this on the pre-procedural checklist. No RCT-level data are attached to this signal; it is a mechanistic alert, not a confirmed safety signal.
Surgical vs. Transcatheter Comparisons
[NOTABLE] The STS risk model for SAVR-after-TAVR (Hawkins, Mehaffey, Badhwar, Bowdish et al.) is the first validated tool quantifying the operative penalty when SAVR follows a prior transcatheter valve. The authorship — the surgical community's core critique group on TAVR indication creep — is deliberate, and their contribution is empirical: the excess hazard of cardiac surgery after TAVR now has a calibrated distribution.
The clinical implication cuts directly against the "TAVR first, surgery later" lifetime-management framing, particularly for patients in their 60s where ESC 2025's tricuspid AV age cutoff of 70 creates genuine ambiguity. ACC/AHA 2020 preferences SAVR for patients under 65 on durability grounds; this risk model provides a second empirical foundation for that preference — reoperative risk after TAVR is not equivalent to reoperative risk after prior SAVR, and treating them as equivalent distorts shared decision-making. BAV patients remain Class IIb for TAVI in both guidelines; this model should feature explicitly in Heart Team discussion for that group, where the reoperative exposure window is longest.
Regulatory & Policy
CMS released its Proposed Decision Memo on TAVR (CAG-00430R2). The reconsideration touches volume requirements, operator experience floors, and — per Bowdish's reading — mandatory registry participation. If registry submission is loosened as coverage expands, the field loses its primary safety-signal detector at the moment it needs one most. The public comment window is the practical intervention point.
Industry & Market
Alkem's majority-stake acquisition of Occlutech extends India-based consolidation into Swiss structural heart tech (LAA occlusion, congenital defect closure devices). Not a valve-primary deal, but relevant to the wider structural heart supplier landscape where regional consolidation is running ahead of clinical differentiation.
Valve Industry Stocks
Edwards Lifesciences (EW)
- Close: $85.73 (-2.40%); 6-mo change +2.72%; 52-wk range $72.30–$96.29
- Market cap $49.4B; P/E trailing 46.34, forward 25.5; Beta 0.85
- Analyst target $99.00 (25 analysts, buy); range $84–$110
- Q2 earnings July 23: EPS est $0.74, revenue est $1.70B
EW is trading sideways heading into earnings after FTC penalty reports. TAVR revenue growth and margin durability remain the bull thesis; the CMS NCD is the near-term catalyst that could reprice the top line either direction.
Medtronic (MDT)
- Close: $83.20 (-0.43%); 6-mo change -14.16%; 52-wk range $73.31–$106.33
- P/E trailing 22.31, forward 12.99; Beta 0.58
- Analyst target $97.84 (25 analysts, buy); range $78–$121
MDT has underperformed peers over six months. Evolut low-risk long-term durability data remain the structural asset in the portfolio, but broader diversification into diabetes and neuromodulation dilutes the valve-specific narrative.
Abbott (ABT)
- Close: $100.68 (+1.87%); 6-mo change -15.77%; 52-wk range $81.97–$137.49
- P/E trailing 28.20, forward 16.60; Beta 0.61
- Analyst target $118.33 (24 analysts, buy); Q3 earnings Oct 14
ABT's structural heart exposure via TriClip competes directly with Edwards's EVOQUE in the transcatheter tricuspid space; the ESC 2025 Class IIa upgrade is a durable tailwind for both franchises.
Boston Scientific (BSX)
- Close: $44.03 (-1.32%); 6-mo change -51.72%; 52-wk range $42.20–$109.50
- Market cap $65.4B; P/E trailing 18.42, forward 11.86; Beta 0.58
- Analyst target $72.43 (28 analysts, strong buy); Q2 earnings July 29
The 52% drawdown is severe and disconnected from underlying cardiovascular revenue growth signals. Sell-side unanimity at strong buy with target well above current price indicates either the analyst community is late to reprice or the sell-off is technical.
Anteris Technologies (AVR.AX)
- Close: A$11.80 (+2.08%); 6-mo change +61.87%; 52-wk range A$4.79–$15.47
- Market cap A$1.1B; forward P/E -5.41 (pre-revenue); Beta 0.73
Anteris continues to trade on DurAVR THV pivotal trial anticipation. Single-analyst coverage limits price-discovery signal.
Market outlook: The pre-earnings setup for the two largest names (EW July 23, BSX July 29) collides with the CMS TAVR NCD comment window and the STS/ACC TVT Registry policy debate. Bull cases rest on volume expansion; bear cases rest on tightened coverage criteria and the possibility that SAVR-after-TAVR risk models redirect younger patients back toward the OR.
Clinical Trial Updates
No new randomized trial readouts today beyond the TRISCEND II echo substudy. Watch for follow-on tricuspid data from Tri.Fr extended follow-up and TRILUMINATE 3-year data, both of which will further calibrate the ESC 2025 Class IIa transcatheter tricuspid recommendation.
Edwards Q2 on July 23 tells us whether low-risk TAVR volumes are still compounding into the CMS decision window — and whether the SAVR-after-TAVR risk model gets any airtime on the analyst call.
— E. Nolan Beckett, MD